Evidence map›Paper›PMID 35486832›Full record

ArticleBlood2022

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.

Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Lindsay D Smith, Francesco Forconi, Bauke V Schomakers, Michel van Weeghel, Dean J Bryant, Jaco A C van Bruggen and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. A guide to B cell metabolism.Nature reviews. Immunology · 2026
    Review
  3. Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Zhenghao ChenExperimental Immunology, and.ORCID 0000-0001-6063-8434
Helga Simon-MolasExperimental Immunology, and.ORCID 0000-0003-2431-6133
Gaspard CretenetExperimental Immunology, and.
Beatriz Valle-ArgosCurve Therapeutics, University of Southampton, Southampton, UK.ORCID 0000-0003-3334-3387
Lindsay D SmithCancer Research UK Centre, Cancer Sciences, University of Southampton, Southampton, UK.
Francesco ForconiDepartment of Haematology, Southampton University Hospital Trust, Southampton, UK.ORCID 0000-0002-2211-1831
Bauke V SchomakersLaboratory Genetic Metabolic Diseases, and.
Michel van WeeghelLaboratory Genetic Metabolic Diseases, and.ORCID 0000-0002-4916-2866
Dean J BryantCancer Research UK Centre, Cancer Sciences, University of Southampton, Southampton, UK.ORCID 0000-0003-3163-608X
Jaco A C van BruggenExperimental Immunology, and.
Fleur S PetersExperimental Immunology, and.ORCID 0000-0002-0509-315X
Jeffrey C RathmellVanderbilt Center for Immunobiology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Gerritje J W van der WindtGenmab, Utrecht, The Netherlands; and.
Arnon P KaterHematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3190-1891
Graham PackhamCancer Research UK Centre, Cancer Sciences, University of Southampton, Southampton, UK.ORCID 0000-0002-9232-5691
Eric ElderingExperimental Immunology, and.ORCID 0000-0003-0561-6640
Oncode Institute · NLCancer Research UK · GBAmsterdam University Medical Centers · NLGenmab (Netherlands) · NLUniversity Hospital Southampton NHS Foundation Trust · GBVanderbilt University Medical Center · US

Funding

Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3M
Cancer Research UK 23669Cancer Research UK 29370NCI NIH HHS R01 CA217987
6 · The paper itself

Abstract

Altered metabolism is a hallmark of both cell division and cancer. Chronic lymphocytic leukemia (CLL) cells circulate between peripheral blood (PB) and lymph nodes (LNs), where they receive proliferative and prosurvival signals from surrounding cells. However, insight into the metabolism of LN CLL and how this may relate to therapeutic response is lacking. To obtain insight into CLL LN metabolism, we applied a 2-tiered strategy. First, we sampled PB from 8 patients at baseline and after 3-month ibrutinib (IBR) treatment, which forces egress of CLL cells from LNs. Second, we applied in vitro B-cell receptor (BCR) or CD40 stimulation to mimic the LN microenvironment and performed metabolomic and transcriptomic analyses. The combined analyses indicated prominent changes in purine, glucose, and glutamate metabolism occurring in the LNs. CD40 signaling mostly regulated amino acid metabolism, tricarboxylic acid cycle (TCA), and energy production. BCR signaling preferably engaged glucose and glycerol metabolism and several biosynthesis routes. Pathway analyses demonstrated opposite effects of in vitro stimulation vs IBR treatment. In agreement, the metabolic regulator MYC and its target genes were induced after BCR/CD40 stimulation and suppressed by IBR. Next, 13C fluxomics performed on CD40/BCR-stimulated cells confirmed a strong contribution of glutamine as fuel for the TCA cycle, whereas glucose was mainly converted into lactate and ribose-5-phosphate. Finally, inhibition of glutamine import with V9302 attenuated CD40/BCR-induced resistance to venetoclax. Together, these data provide insight into crucial metabolic changes driven by the CLL LN microenvironment. The prominent use of amino acids as fuel for the TCA cycle suggests new therapeutic vulnerabilities.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellCD40 AntigensGlucoseGlutamineHumansLymph NodesReceptors, Antigen, B-CellTumor MicroenvironmentCD40 AntigensGlucoseGlutamineReceptors, Antigen, B-Cell

Identifiers

PMID35486832
PMCPMC10118070
OpenAlexW4225133395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.